Table 1.
Patient characteristics
| Characteristics | Results |
|---|---|
| Age [years], median, mean, range | 70, 69, 57–80 |
| Time between ADT initiation and second [68Ga]Ga-PSMA-PET [days], median, mean, range | 155, 158, 61–289 |
| PSA value at [68Ga]Ga-PSMA-PET (T1), median, mean, range [ng/ml] | 29.1, 39.0, 2.5–107.0 |
| PSA value at [68Ga]Ga-PSMA-PET (T2), median, mean, range [ng/ml] | 0.71, 1.24, 0.05–4.91 |
| Lesions T1 versus T2 | |
| Prostate tumor [n: patients; n: lesions] | 21 versus 17; 24 versus 18 |
| Lymph node metastases [n: patients; n: lesions] | 16 versus 10; 56 versus 20 |
| Bone metastases [n: patients; n: lesions] | 14 versus 10; 27 versus 12a |
| Sum [n: lesions] | 107 versus 50a |
| ∑ PSMA derived tumor volume (PSMA-TV) of all lesions at T1, sum [ml] | 505.69 |
| ∑ PSMA derived tumor volume (PSMA-TV) of all lesions T2, sum [ml], (% of T1) | 121.51 (24.0%) |
| ∑ Total lesion PSMA (TL-PSMA) of all lesions at T1, sum [ml] | 9016.32 |
| ∑ Total lesion PSMA (TL-PSMA) of all lesions at T2, sum [ml], (% of T1) | 1256.91 (13.9%) |
aTwo of these were new in T2